Selvita to Release the Most Recent Results from Its Oncology Programs at the AACR Annual Meeting 2015

selvita logo

Krakow, Poland, April 17, 2015 / B3C newswire / --  Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2015, which will take place on 18 – 22 April 2015 in Philadelphia, PA, USA.


Data presented during this conference will include recent results from Selvita’s most promising oncology programs: SEL24 program, a first-in-class selective dual inhibitor of PIM and FLT3 kinases which has just entered the IND-enabling studies, and  SEL120 program, a selective CDK8 inhibitor with therapeutic potential in colorectal cancer.

Above mentioned results of SEL24 and SEL120 programs, will be presented respectively:

A poster presentation entitled "First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies" is scheduled to be presented at the poster session "Kinase Inhibitors and Other Targets“, on Wednesday, April 22, between 8:00 AM and 12:00 PM.

A poster presentation entitled "Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer" is scheduled to be presented at the poster session "Cell Cycle, DNA, and Transcription Targets”, on Monday, April 20, between 8:00 AM and 12:00 PM

“The upcoming Annual AACR Meeting 2015 is an important event for us. We’ve just initiated IND-enabling studies for the SEL24 program, a selective inhibitor of PIM and FLT3 kinases, with potential application in the treatment of acute myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma and other neoplastic disorders. This was a major step both for the program and the Company, and we’re very excited to be getting closer to the point where we can offer patients a potentially breakthrough treatment" - said Dr. Krzysztof Brzózka, Chief Scientific Officer and Executive VP, at Selvita. "Our CDK8 inhibitor, SEL120, is progressing swiftly through the preclinical development and we’re hoping that soon we will deliver an upgrade in the treatment of the colorectal cancer patients" – he adds.  

About Selvita
Selvita is a drug discovery company engaged in the research and development of breakthrough oncology therapies, as well as provision of  drug discovery services.  Currently Selvita employs 232 scientists, including 79 PhDs, with extensive experience in area of life sciences. Selvita laboratories possess the GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita offices are located in Greater Boston Area and Krakow, Poland, and the company is listed on the Main Market of Warsaw Stock Exchange (WSE:SLV).


Natalia Baranowska
This email address is being protected from spambots. You need JavaScript enabled to view it.
+48 784 069 418


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.